Proton pump inhibitors are associated with lower gastrointestinal tract bleeding in low-dose aspirin users with ischaemic heart disease

Digestive and Liver Disease

Volumn 47, Issue 9, 2015, Pages 757-762

  Miyake, Kazumasa ^a   Akimoto, Teppei ^a   Hanada, Yuriko ^a   Nagoya, Hiroyuki ^a   Kodaka, Yasuhiro ^a   Ueki, Nobue ^a   Kusunoki, Masafumi ^a   Kawagoe, Tetsuro ^a   Futagami, Seiji ^a   Takahashi, Yasuhiro ^a   Takano, Hitoshi ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Gastrointestinal bleeding; Histamine 2 receptor antagonists; Low dose aspirin; Oroton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; WARFARIN; ANTITHROMBOCYTIC AGENT;

AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING; COMBINATION DRUG THERAPY; COMPLICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODEL;

AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84939271842     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.05.020     Document Type: Article

References (55)

1. Dalen J.E. Aspirin to prevent heart attack and stroke: what's the right dose. American Journal of Medicine 2006, 119:198-202.
2. Lanas A., Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Current Medical Research and Opinion 2007, 23:163-173.
3. Sostres C., Lanas A. Gastrointestinal effects of aspirin. Nature Reviews Gastroenterology & Hepatology 2011, 8:385-394.
4. Weisman S.M., Graham D.Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Archives of Internal Medicine 2002, 162:2197-2202.
5. Rao S.V., O'Grady K., Pieper K.S., et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. American Journal of Cardiology 2005, 96:1200-1206.
6. Nikolsky E., Stone G.W., Kirtane A.J., et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. Journal of the American College of Cardiology 2009, 54:1293-1302.
7. Bjarnason I., Hayllar H., Macpherson A.J., et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104:1832-1847.
8. Langman M.J.S., Morgan L., Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and hemorrhage. British Medical Journal 1985, 290:347-349.
9. Allison M.C., Howatson A.G., Torrance C.J., et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. New England Journal of Medicine 1992, 327:749-754.
10. Lanas A., Sekar M.C., Hirschowitz B.I. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992, 103:862-869.
11. Lanas A., Serrano P., Bajador E., et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997, 112:683-689.
12. Wallace J.L. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World Journal of Gastroenterology 2013, 19:1861-1876.
13. Lanas A., García-Rodríguez L.A., Polo-Tomás M., et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. American Journal of Gastroenterology 2009, 104:1633-1641.
14. Wallace J.L., Syer S., Denou E., et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011, 141:1314-1322.
15. Fortun P.J., Hawkey C.J. Nonsteroidal antiinflammatory drugs and the small intestine. Current Opinion in Gastroenterology 2005, 21:169-175.
16. Serrano P., Lanas A., Arroyo M.T., et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Alimentary Pharmacology and Therapeutics 2002, 16:1945-1953.
17. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. American Journal of Gastroenterology 2007, 102:507-515.
18. Casado Arroyo R., Polo-Tomas M., Roncalés M.P., et al. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart 2012, 98:718-723.
19. Thorens J., Froehlich F., Schwizer W., et al. Bacterial overgrowthduring treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996, 39:54-59.
20. Lanas Á., Carrera-Lasfuentes P., Arguedas Y., et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clinical Gastroenterology and Hepatology 2015, 13:906-912.
21. Abraham N.S., Hlatky M.A., Antman E.M., et al. ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. American Journal of Gastroenterology 2010, 105:2533-2549.
22. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2002, 4:CD002296.
23. Izaks G.J., Westendorp R.G., Knook D.L. The definition of anemia in older persons. Journal of the American Medical Association 1999, 281:1714-1717.
24. Zakai N.A., Katz R., Hirsch C., et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The Cardiovascular Health Study. Archives of Internal Medicine 2005, 165:2214-2220.
25. Culleton B.F., Manns B.J., Zhang J., et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006, 107:3841-3846.
26. Patel K.V., Harris T.B., Faulhaber M., et al. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 2007, 109:4663-4670.
27. Semba R.D., Guralnik J.M., Chaves P., et al. Iron status and anemia in a populationbased study of women with and without disability living in the community: The Women's Health and Aging Studies. Haematologica 2004, 89:357-358.
28. Penninx B.W., Pahor M., Cesari M., et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. Journal of the American Geriatrics Society 2004, 52:719-724.
29. Chaves P.H., Xue Q.L., Guralnik J.M., et al. What constitutes normal hemoglobin concentration in community-dwelling disabled older women. Journal of the American Geriatrics Society 2004, 52:1811-1816.
30. Cohen M. Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Mayo Clinic Proceedings 2009, 84:149-160.
31. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Journal of the American College of Cardiology 1988, 11:1-11.
32. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. New England Journal of Medicine 1993, 329:673-682.
33. Serebruany V.L., Atar D. Assessment of bleeding events in clinical trials - proposal of a new classification. American Journal of Cardiology 2007, 99:288-290.
34. Nakayama A., Matsuo H., Nakaoka H., et al. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Scientific Reports 2014, 4:5227.
35. Matsuo H., Takada T., Nakayama A., et al. ABCG2 dysfunction increases the risk of renal overload hyperuricemia. Nucleosides, Nucleotides and Nucleic Acids 2014, 33:266-274.
36. Matsuo H., Nakayama A., Sakiyama M., et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Scientific Reports 2014, 4:3755.
37. Takada T., Ichida K., Matsuo H., et al. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion. Nucleosides, Nucleotides and Nucleic Acids 2014, 33:275-281.
38. Atar S., Cannon C.P., Murphy S.A., et al. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. American Heart Journal 2006, 151:976.e1-976.e6.
39. Diomede L., Albani D., Sottocorno M., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21:1327-1332.
40. Chen J.C., Huang K.C., Wingerd B., et al. HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Experimental Cell Research 2004, 301:305-319.
41. Werner N., Nickenig G., Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Research in Cardiology 2002, 97:105-116.
42. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. American Journal of Cardiology 2005, 96:24F-33F.
43. Heeba G.H., Hassan M.K., Amin R.S. Gastroprotective effect of simvastatin against indomethacin-induced gastric ulcer in rats: role of nitric oxide and prostaglandins. European Journal of Pharmacology 2009, 607:188-193.
44. Yamato M., Watanabe T., Higuchi K., et al. Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice. Digestive Diseases and Sciences 2007, 52:2833-2839.
45. Blache D., Ojeda C. Comparative inhibitory effects of dihydropyridines on platelet aggregation, calcium uptake and cyclic AMP concentration. Pharmacology 1992, 45:250-259.
46. Odawara A., Katoh M., Karasawa T., et al. Inhibitory effect of clentiazem (TA-3090) on platelet aggregation - alone and in combination with aspirin or ticlopidine. Thrombosis Research 1994, 75:109-119.
47. Wallén N.H., Held C., Rehnqvist N., et al. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. American Journal of Cardiology 1995, 75:1-6.
48. Berkels R., Klaus W., Boller M., et al. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thrombosis and Haemostasis 1994, 72:309-312.
49. Pahor M., Guralnik J.M., Furberg C.D., et al. Risk of gastrointestinal hemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996, 347:1061-1065.
50. Kaplan R.C., Heckbert S.R., Koepsell T.D., et al. Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Archives of Internal Medicine 2000, 160:1849-1855.
51. Hung C.R. Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats. Chinese Journal of Physiology 2007, 50:315-325.
52. Suzuki Y., Ishihara M., Segami T., et al. Anti-ulcer effects of antioxidants, quercetin, alpha-tocopherol, nifedipine and tetracycline in rats. Japanese Journal of Pharmacology 1998, 78:435-441.
53. Coşkun T., Alican I., Gürbüz V., et al. Influence of gallopamil on the gastric effects of stress in conscious rats. Pharmacology 1996, 52:199-206.
54. Endo H., Sakai E., Higurashi T., et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Digestive and Liver Disease 2012, 44:833-838.
55. Davies N.M. Sustained release and enteric coated NSAIDs: are they really GI safe. Journal of Pharmacy and Pharmaceutical Sciences 1999, 2:5-14.